Back to top
more

Seres Therapeutics (MCRB)

(Delayed Data from NSDQ)

$0.73 USD

0.73
5,811,786

-0.03 (-4.01%)

Updated Apr 24, 2024 03:59 PM ET

After-Market: $0.72 -0.01 (-1.30%) 7:58 PM ET

Zacks Rank:

This is our short term rating system that serves as a timeliness indicator for stocks over the next 1 to 3 months. How good is it? See rankings and related performance below.

Zacks Rank Definition Annualized Return
1Strong Buy24.20%
2Buy18.04%
3Hold9.52%
4Sell5.20%
5Strong Sell2.60%
S&P50011.13%

Zacks Rank Education - Learn about the Zacks Rank

Zacks Rank Home - Zacks Rank resources in one place

Zacks Premium - The only way to fully access the Zacks Rank

3-Hold of 5     3    

Style Scores:

The Style Scores are a complementary set of indicators to use alongside the Zacks Rank. It allows the user to better focus on the stocks that are the best fit for his or her personal trading style.

The scores are based on the trading styles of Value, Growth, and Momentum. There's also a VGM Score ('V' for Value, 'G' for Growth and 'M' for Momentum), which combines the weighted average of the individual style scores into one score.

Value Score A
Growth Score A
Momentum Score A
VGM Score A

Within each Score, stocks are graded into five groups: A, B, C, D and F. As you might remember from your school days, an A, is better than a B; a B is better than a C; a C is better than a D; and a D is better than an F.

As an investor, you want to buy stocks with the highest probability of success. That means you want to buy stocks with a Zacks Rank #1 or #2, Strong Buy or Buy, which also has a Score of an A or a B in your personal trading style.

Zacks Style Scores Education - Learn more about the Zacks Style Scores

F Value C Growth C Momentum D VGM

Industry Rank:

The Zacks Industry Rank assigns a rating to each of the 265 X (Expanded) Industries based on their average Zacks Rank.

An industry with a larger percentage of Zacks Rank #1's and #2's will have a better average Zacks Rank than one with a larger percentage of Zacks Rank #4's and #5's.

The industry with the best average Zacks Rank would be considered the top industry (1 out of 265), which would place it in the top 1% of Zacks Ranked Industries. The industry with the worst average Zacks Rank (265 out of 265) would place in the bottom 1%.

Zacks Rank Education -- Learn more about the Zacks Rank
Zacks Industry Rank Education -- Learn more about the Zacks Industry Rank

Top 31% (78 out of 252)

Industry: Medical - Biomedical and Genetics

Zacks Premium FeatureView All Zacks #1 Ranked Stocks

Better trading starts here.

Zacks News

Halozyme Therapeutics (HALO) Surges 5.6%: Is This an Indication of Further Gains?

by Zacks Equity Research

Halozyme Therapeutics (HALO) was a big mover last session on higher-than-average trading volume. The latest trend in earnings estimate revisions might not help the stock continue moving higher in the near term.

Seres Therapeutics (MCRB) Misses Q2 Earnings Estimates

by Zacks Equity Research

Seres Therapeutics (MCRB) delivered earnings and revenue surprises of -34.55% and 0.78%, respectively, for the quarter ended June 2023. Do the numbers hold clues to what lies ahead for the stock?

Seres Therapeutics (MCRB) Reports Q1 Loss, Misses Revenue Estimates

by Zacks Equity Research

Seres Therapeutics (MCRB) delivered earnings and revenue surprises of 0% and 126.10%, respectively, for the quarter ended March 2023. Do the numbers hold clues to what lies ahead for the stock?

Analysts Estimate Alector (ALEC) to Report a Decline in Earnings: What to Look Out for

by Zacks Equity Research

Alector (ALEC) doesn't possess the right combination of the two key ingredients for a likely earnings beat in its upcoming report. Get prepared with the key expectations.

Seres Therapeutics (MCRB) May Report Negative Earnings: Know the Trend Ahead of Q1 Release

by Zacks Equity Research

Seres Therapeutics (MCRB) doesn't possess the right combination of the two key ingredients for a likely earnings beat in its upcoming report. Get prepared with the key expectations.

Strength Seen in Seres Therapeutics (MCRB): Can Its 5.8% Jump Turn into More Strength?

by Zacks Equity Research

Seres Therapeutics (MCRB) was a big mover last session on higher-than-average trading volume. The latest trend in earnings estimate revisions might not help the stock continue moving higher in the near term.

Seres Therapeutics (MCRB) Moves 10.9% Higher: Will This Strength Last?

by Zacks Equity Research

Seres Therapeutics (MCRB) saw its shares surge in the last session with trading volume being higher than average. The latest trend in earnings estimate revisions may not translate into further price increase in the near term.

Seres Therapeutics (MCRB) Reports Q4 Loss, Misses Revenue Estimates

by Zacks Equity Research

Seres Therapeutics (MCRB) delivered earnings and revenue surprises of -31.71% and 89.21%, respectively, for the quarter ended December 2022. Do the numbers hold clues to what lies ahead for the stock?

Omega Therapeutics, Inc. (OMGA) Reports Q4 Loss, Tops Revenue Estimates

by Zacks Equity Research

Omega Therapeutics, Inc. (OMGA) delivered earnings and revenue surprises of -3.23% and 13.08%, respectively, for the quarter ended December 2022. Do the numbers hold clues to what lies ahead for the stock?

Biogen Inc. (BIIB) Q4 Earnings and Revenues Beat Estimates

by Zacks Equity Research

Biogen Inc. (BIIB) delivered earnings and revenue surprises of 15.38% and 4.13%, respectively, for the quarter ended December 2022. Do the numbers hold clues to what lies ahead for the stock?

Seres Therapeutics (MCRB) Reports Q3 Loss, Lags Revenue Estimates

by Zacks Equity Research

Seres Therapeutics (MCRB) delivered earnings and revenue surprises of -8.89% and 71.97%, respectively, for the quarter ended September 2022. Do the numbers hold clues to what lies ahead for the stock?

Seres Therapeutics (MCRB) Reports Q2 Loss, Lags Revenue Estimates

by Zacks Equity Research

Seres Therapeutics (MCRB) delivered earnings and revenue surprises of -20.69% and 79.84%, respectively, for the quarter ended June 2022. Do the numbers hold clues to what lies ahead for the stock?

Seres Therapeutics (MCRB) Reports Q1 Loss, Misses Revenue Estimates

by Zacks Equity Research

Seres Therapeutics (MCRB) delivered earnings and revenue surprises of -8.93% and 79.01%, respectively, for the quarter ended March 2022. Do the numbers hold clues to what lies ahead for the stock?

Seres Therapeutics (MCRB) Reports Q4 Loss, Lags Revenue Estimates

by Zacks Equity Research

Seres Therapeutics (MCRB) delivered earnings and revenue surprises of -22.22% and 62.94%, respectively, for the quarter ended December 2021. Do the numbers hold clues to what lies ahead for the stock?

Acadia Pharmaceuticals (ACAD) Reports Q4 Loss, Lags Revenue Estimates

by Zacks Equity Research

Acadia (ACAD) delivered earnings and revenue surprises of -12.50% and 3.09%, respectively, for the quarter ended December 2021. Do the numbers hold clues to what lies ahead for the stock?

Seres Therapeutics (MCRB) Q3 Earnings and Revenues Beat Estimates

by Zacks Equity Research

Seres Therapeutics (MCRB) delivered earnings and revenue surprises of 253.19% and 1681.10%, respectively, for the quarter ended September 2021. Do the numbers hold clues to what lies ahead for the stock?

Analysts Estimate Seres Therapeutics (MCRB) to Report a Decline in Earnings: What to Look Out for

by Zacks Equity Research

Seres Therapeutics (MCRB) doesn't possess the right combination of the two key ingredients for a likely earnings beat in its upcoming report. Get prepared with the key expectations.

Seres Therapeutics (MCRB) Reports Q2 Loss, Tops Revenue Estimates

by Zacks Equity Research

Seres Therapeutics (MCRB) delivered earnings and revenue surprises of -29.27% and 19.75%, respectively, for the quarter ended June 2021. Do the numbers hold clues to what lies ahead for the stock?

Biotech Stock Roundup: BIIB's Q2 Earnings Update & Other Updates From AMGN, INCY

by Zacks Equity Research

The biotech sector was in focus last week on earnings results from Biogen (BIIB) and updates from Incyte (INCY) and others.

Analysts Estimate Seres Therapeutics (MCRB) to Report a Decline in Earnings: What to Look Out for

by Zacks Equity Research

Seres Therapeutics (MCRB) doesn't possess the right combination of the two key ingredients for a likely earnings beat in its upcoming report. Get prepared with the key expectations.

Implied Volatility Surging for Seres Therapeutics (MCRB) Stock Options

by Zacks Equity Research

Investors need to pay close attention to Seres Therapeutics (MCRB) stock based on the movements in the options market lately.

Seres Therapeutics (MCRB) Reports Q1 Loss, Tops Revenue Estimates

by Zacks Equity Research

Seres Therapeutics (MCRB) delivered earnings and revenue surprises of -18.18% and 7.83%, respectively, for the quarter ended March 2021. Do the numbers hold clues to what lies ahead for the stock?

Seres Therapeutics (MCRB) Reports Q4 Loss, Tops Revenue Estimates

by Zacks Equity Research

Seres Therapeutics (MCRB) delivered earnings and revenue surprises of 30.77% and 99.98%, respectively, for the quarter ended December 2020. Do the numbers hold clues to what lies ahead for the stock?

Earnings Preview: Seres Therapeutics (MCRB) Q4 Earnings Expected to Decline

by Zacks Equity Research

Seres Therapeutics (MCRB) doesn't possess the right combination of the two key ingredients for a likely earnings beat in its upcoming report. Get prepared with the key expectations.

5 Medical Outperformers That Might Lose Steam in 2021

by Zacks Equity Research

Here we discuss some biotech stocks, which are up this year so far but might not be good additions to your portfolio.